BioSpace News Archive

Diadem SpA, a company developing the first blood-based test for the early prediction of progression to Alzheimer’s disease, announced that its researchers have developed computational methods that enable its AlzoSure® Predict prognostic technology to accurately identify individuals who will rapidly progress to AD within two years’ time.

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary total revenue for the fourth quarter, ongoing activity from the commercial portfolio, including TAVALISSE® (fostamatinib disodium hexahydrate) tablets and REZLIDHIA™ (olutasidenib) capsules, and upcoming catalysts for 2023.

Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing Company™, today announced that it entered into a partnership with Aviva Systems Biology, a leading provider of antibody, protein, and immunoassay reagent products with an extensive portfolio of over 20,000 antibodies against more than 15,000 human gene targets.

Quantum-Si and Biovista Partner to Provide AI-Driven Deep Proteomics Insights from the Platinum ™ Next-Generation Protein Sequence Platform Output.

Cellworks Group Inc.today announced the launch of its Precision Drug Development business units aimed at accelerating time-to-market for drug development and reviving previously studied but unapproved pharmaceutical assets through predictive biosimulation.

2seventy bio, Inc. (Nasdaq: TSVT) announced today key corporate milestones and financial outlook for 2023.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today announced a strategic update, including portfolio reprioritization and research and development realignment.

DexCom, Inc. announced today the appointment of Teri Lawver to the newly created role of chief commercial officer.

XEN1101 Phase 3 Epilepsy Program Ongoing in Focal Onset Seizures and Recently Initiated in Primary Generalized Tonic Clonic Seizures.